secwatch.observer — SEC 8-K summary
======================================

Issuer:     NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC)
CIK:        0001500198
Form:       8-K
Filed at:   2025-12-17T23:59:59+00:00
Accession:  0001213900-25-122541
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NeuroOne reports Q4 product revenue of $2.7M (+907% YoY); full-year loss narrows 71%
--------------------------------------------------------------------------------

- Product revenue $2.7M in Q4 FY2025, up 907% YoY; full year product revenue $9.1M, up 163% YoY.
- Product gross margin improved to 55.8% in Q4 and 56.5% for FY2025, up from 31.3% in FY2024.
- Net loss improved 71% to $3.6M ($0.09/share) for FY2025; Q4 net loss $1.6M ($0.03/share) vs $3.4M ($0.11) YoY.
- FDA 510(k) clearance for OneRF Trigeminal Nerve Ablation System; first two trigeminal neuralgia patients treated.
- Cash & equivalents $6.6M (up from $1.5M); no debt; funded through fiscal 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1500198/000121390025122541/0001213900-25-122541-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1500198/000121390025122541/ea0269921-8k_neuroone.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-122541

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer